Introduction
According to the Centers for Disease Control, heart failure (HF) remains a pervasive condition with high morbidity and mortality, affecting 5.8 million people in the United States and 23 million worldwide. For patients with refractory end-stage HF, heart transplantation is the "gold standard" for definitive treatment. However, the demand for heart transplantation has consistently exceeded the availability of donor hearts, with approximately 3191 orthotopic heart transplantations performed in the United States in 2016 despite an estimated 100 000 to 250 000 patients with New York Heart Association (NYHA) class IIIB or IV symptoms that are refractory to medical treatment, making such patients potential transplant candidates (1) (2) (3) . As such, the need for mechanical circulatory support (MCS) to treat patients with end-stage heart failure has become paramount. In this review, we focus on the history, advancements, and current use of durable MCS device therapy in the treatment of advanced heart failure.
Background
The use of mechanical circulatory support was first described in 1953 by John Gibbon et al within the context of cardiopulmonary bypass (CPB), where the surgeon's now famous heart-lung machine was used for a total of 26 min in the closure of an atrial septal defect (4) . In the 1960s, Drs. Michael DeBakey and Frank Spencer observed the benefits of CPB extending beyond the operating room and into the postsurgical recovery period, where resting the heart on CPB for longer periods of time allowed for recovery of ventricular function in patients with cardiogenic shock (5) . As a result, the first generation of pneumatic ventricular assist devices (VAD) began to shape the landscape of cardiothoracic surgery, meeting the need for longer-term cardiac support. The first of such devices were implanted by Crawford, Liotta, and DeBakey in 1963 in a patient who experienced a cardiac arrest after aortic valve replacement.
Following this and several other landmark cases, the National Heart and Lung Institute, which would become the National Heart, Lung, and Blood Institute (NHLBI) as it is known today, convened a number of expert panels to direct the development of durable MCS devices and led to the approval of the first clinical trials for VAD placement in humans by 1975. Soon after, the US Food and Drug Administration (FDA) approved devices for use as bridges to heart transplant following a landmark transplant of a Jarvik-7 total artificial heart (TAH) into a patient who survived for 112 days (6) . From this moment forward, the FDA began approving several devices for use as bridges to heart transplant, laying the groundwork for more modern VADs (7) .
Indications
Despite the tremendous progress in research and technology that has allowed for the development of more advanced durable MCS devices, specific guidelines for device candidacy remain difficult to define. Assessment of patients involves multiple steps and an interdisciplinary approach to define issues such as goals of therapy, heart failure status, preoperative risk, anatomic considerations such as body habitus for the accommodation of devices, comorbid conditions affecting recovery, transplant eligibility, and availability of psychosocial support, among others. For the purposes of this review, we will focus on defining aspects of device candidacy.
Goals of care
General goals of device therapy were defined by the Centers for Medicare and Medicaid Services (CMS) in 1984. Since then, goals of therapy have been shaped into five distinct categories as outlined in Table 1 . Despite these designations, patients may shift from one category to another depending on a number of factors; for example, a patient who is too sick to undergo cardiac transplantation may be treated with device therapy as BTR, after which he or she may be reassigned to BTT upon demonstrating stability in clinical status. Conversely, some patients who are transplant eligible yet who experience acceptable quality of life with device therapy may ultimately be reassigned to DT (8) (9) (10) .
Patient selection
In general, MCS device therapy is reserved for patients with end-stage heart failure refractory to medical therapy. Per the most recent HF guidelines published in 2013, the American College of Cardiology and American Heart Association broadly assign candidacy for durable MCS to patients with stage D HF with reduced ejection fraction (11) . Data from the landmark Randomized Evolution of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) and HeartMate II DT trials were used to obtain FDA approval for device implantation under DT strategy, which comprises 38.2% of all durable MCS devices implanted to date (10) . These criteria are now used for reimbursement purposes under CMS regulation and are listed in Table 2 . Nevertheless, there are currently no widely accepted criteria used in the assessment of device candidacy (8) .
In general, preoperative assessment of patient candidacy is rigorous and includes a thorough history and physical examination, laboratory testing, as well as noninvasive imaging and invasive testing for hemodynamic data. Prior studies have demonstrated poor outcomes with patients who have a history of end-stage renal or hepatic disease as indicated by laboratory results demonstrating impaired hepatic function or elevated levels of blood urea nitrogen and creatinine. Patients with a history of cardiac cachexia as defined by BMI <20 or less than 80% of ideal body weight and laboratory findings of low albumin and prealbumin have also been associated with poor postoperative outcomes (12, 13) .
Preoperative imaging focuses significantly on evaluation of right ventricular (RV) function, as right heart failure (RHF) portends a poor prognosis with ≥20% reduction in perioperative survival. In 2013, the Interagency Registry for Mechanically Assisted Circulatory Support (INTER-MACS) published criteria defining RHF as characterized by both clinical manifestations and objective measurements of elevated central venous pressure (CVP). The agency further categorizes RHF into four categories based on severity: mild, moderate, severe, and severeacute (14) . Prior to these published definitions, studies reported the incidence of RHF over a large range 
Mechanics and Device Evolution
Durable MCS can be classified as a LVAD, right ventricular assist device, biventricular assist device, or TAH. Currently, there are eight devices approved by the FDA and clinically used for long-term MCS and tracked by the INTERMACS registry, as listed in (Table 4 ). All eight are approved for BTT but only two (Thoratec HeartMate XVE, and Thoratec HeartMate II) are approved for DT and five (EXCOR BerlinHeart, Sycardia TAH, Thoratec Heartmate II, MicroMed DeBakey HeartAssist, and HeartWare HVAD) for use in the pediatric population.
Though VADs for BTT have been studied in clinical trials since the early 1990s and FDA-approved since 1998, the first study to examine outcomes in VAD versus optimum medical therapy in DT for transplant-ineligible, end-stage HF patients was not produced until 2001. The landmark REMATCH trial found a 27% absolute improvement in survival rates at 1 year postrandomization in the LVAD group as compared to the medical therapy group (52% vs. 25%, p = 0.002), with further demonstration of 48% reduction of all-cause mortality in the LVAD group by survival analysis (relative risk 0.52, 95% CI 0.34 to 0.78, p = 0.001) (23) . Following this study, the Thoratec vented electric left ventricular assist system, a pulsatile, electrically driven VAD studied in the REMATCH trial, as well as an improved Thoratec HeartMate XVE became the first VADs to be FDA-approved for DT. First-generation VADs were designed to simulate native cardiopulmonary circulation, with volume-displacement chambers that would fill, then empty, either by a pneumatic or later, electrical pump. Though these devices made a significant impact on quality of life for patients by allowing them to leave the hospital and ambulate free of connections to stationary MCS, they were still bulky and cumbersome; such initial VADs weighed 1255 g and required peritoneal implantation of the prosthetic left ventricle and pump with a driveline connecting the internal components to an external driver and battery-operated power source. Consequently, initial VADs were limited to recipients who had a body surface area of at least 1.5 m 2 for device accommodation, severely restricting women and adolescents from device candidacy, and posed significant risks for pump pocket, driveline infections, and device failure. First-generation devices were also noisy and power-inefficient given the pulsatile nature, requiring battery recharging every 4 h to displace 390 mL up to 120 times per minute. As such, device malfunction and replacements with first-generation VADs were high, reported at 0.75 devices/patient year and 0.51 devices/patient year, respectively (23, 24) .
Device evolution and second-generation VADs were designed with the goals of miniaturization, improved efficiency, and reduced complications from infection and device failure (Figure 1 ). In the early 2000s, rotary blood pumps were designed for second-generation devices such as the Thoratec HeartMate II, Jarvik 2000, and MicroMed HeartAssist. Rotary pumps operated via continuous flow and presented several advantages including smaller size, reduction in extraneous components such as valves, higher rotational speeds, amounting to compact VADs such as the HeartMate II, which weighed a mere 281 g and contained only 63 mL volume of blood in its pump but cycled up to 15 000 rotations per minute on 10 h of battery life (24 (25) . As a result, the HeartMate II CF VAD was FDA-approved and became the standard of care for BTT in 2008, after which survival in HeartMate II BTT patients has been reported as high as 81% at 1 year, 76% at 2 years, and 68% at 4 years postimplantation in single-center studies (26) .
Third-generation VADs include a group of centrifugal CF pumps, which comprise a bladed disk spinning in a contained cavity. The centrifugal CF pump was designed to allow centrifugal flow of fluid as opposed to linear flow of the axial CF pumps, thereby decreasing suction at times of low flow and risk of left ventricular suck-down and ventricular arrhythmias. Further modifications to bearing design have also allowed for more streamlined function and reduced complications of thrombosis, hemolysis, and device wear due to contactless bearings as seen in hydrodynamic, electromagnetic, and permanent magnet rotors.
Parallel advancements have been made in the streamlining of the TAH. As the only commercially available, FDAapproved device in this category, the Syncardia TAH has accomplished its own engineering feats; once dependent on a number of external parts including a large power console that prevented patients from hospital discharge, the Syncardia TAH now occupies only 400 cm of space within the chest and is powered by a compact, portable Freedom driver. Though no longer clinically used, the AbioCor TAH remains the only self-contained, completely internalized TAH implanted in humans to date. Excluding (29) . This is in contrast to device implantation for the pediatric population, which saw a larger number of pulsatile LVADs (Berlin Heart EXCOR) accounting for the largest single category, 48.9%, of device implantations in patients age 0-5 years of age (10, 30) . Since achieving the European Conformit e Europ eenne mark addendum in 2012 for long-term, DT-equivalent use, the more compact HeartWare HVAD has been more commonly implanted in Europe and now surpasses 10 000 implantations worldwide.
Survival
Survival in end-stage HF is grim, with 1-year survival rates reported at less than 50% and only 6-25% for those with ionotropic agent dependence (23, 31, 32) . After MCS device therapy became the "gold standard" of treatment for end-stage HF patients based on results of the REMATCH and HeartMate II BTT trials (Figure 2) , the Investigation of Nontransplant-Eligible Patients Who Are Ionotrope Dependent (INTrEPID) trial was undertaken to investigate the benefit of device therapy for the sickest group of patients. The study compared LVAD therapy with optimum medical therapy (OMT) in 55 patients with NYHA functional class IV symptoms and ionotrope dependence and found improved survival at 6 months (46% vs. 22%, p = 0.03) and 12 months (27% vs. 11%, p = 0.02) in the LVAD treatment arm. Additionally, 85% of patients in the LVAD arm experienced an improvement in NYHA functional class by at least two classes, compared to no patients in the OMT group. Though survival was worse in both arms as compared to their respective cohorts in the REMATCH trial because of the increased severity of HF in study patients, the INTrEPID trial results reinforced results produced by the REMATCH trial and effectively excluded OMT alone as standard of care for end-stage, transplant-ineligible patients. Interestingly, five of the INTrEPID trial LVAD patients were successfully bridged to transplantation, highlighting the important need for LVADs in this role. Prior to the FDA approval of LVADs for BTT, a reported 11-37% of LVAD-treated and subsequently transplanted patients would have been precluded from transplantation (33, 34) . In recent eras, 37% of cardiac transplantations have been bridged with MCS, and prospective analyses have demonstrated comparable survival in bridged patients as compared to those previously treated with ionotropes only (35) .
Patients with MCS device implantation for BTT continue to do better than those under the DT strategy as evidenced by a survival rate of 75% versus 57%, respectively, at 3 years postimplantation, attributable in part to older age and higher comorbidities of the DT cohort (10, 36) . Nevertheless, improvements in functional status and quality of life have allowed the use of MCS for DT to rise steadily, with the largest increase (20.5%) in the years immediately following FDA approval of the HeartMate II for DT (37) . In the direct comparison between the continuous flow HeartMate II and the pulsatile flow HeartMate XVE, Slaughter et al demonstrated superiority in the CF device as measured by 2-year survival free of disabling stroke or device replacement in 46% versus 11% of patients (p < 0.001) (38) .
The introduction of third-generation, CF VADs has further expanded options for patients who were once considered transplant-ineligible. In 2011, the first multicenter, prospective study to examine outcomes after implantation of the HeartWare VAD (HVAD) included 50 patients in a single-arm study that demonstrated 90% survival at 6 months, with 40% undergoing transplantation and subsequent survival of 95% at 6-months posttransplant. Follow-up at 24 months in patients receiving ongoing HVAD support also showed a promising 39% improvement in survival over SHFM calculated survival rates in the same patients (79% vs. 40%) (39) . At the conclusion of this European study, the ADVANCE trial confirmed HVAD noninferiority in 140 patients when compared to 499 matched controls from the INTERMACS database, with 90.7% success as defined by transplant, recovery explant, or survival with HVAD at 6 months in the study arm versus 90.1% (p < 0.001) in the control group. Regression modeling at 30, 60, 120, and 360 days postenrollment consistently showed equivalent survival in the HVAD and control groups with additional improvements in functional statuses measured by 6-min walk test evaluation and quality of life scores, thereby leading to the FDA approval of HVAD for BTT in 2012 (40) .
In examining third-generation, centrifugal CF VADs regardless of implantation strategy, Mehra et al recently demonstrated superiority of the fully magnetically levitated, centrifugal flow CF VAD Heartmate 3 (HM3) as compared to the axial flow CF VAD Heartmate II in MOMENTUM 3 IDE Clinical Study Protocol (NCT92224755), a multicenter, prospective, randomized study of 294 patients. The study found that 86.2% of patients in the HM3 group achieved primary endpoints of survival free of death, disabling stroke, or reoperation at 6 months postimplantation as compared to those in the Heartmate II group (p < 0.001). This improvement in survival was attributed to a lower rate of pump thrombosis leading to failure to unload the left ventricle (0 events vs. 18 events, p < 0.001) and subsequent need for reoperation for device exchange or removal with urgent transplantation (1 patient vs. 11 patients, p = 0.002) (41) . To date, this is the first trial to enroll patients for study irrespective of device strategy (BTT vs. DT); the study will continue enrolling patients in their continued access protocol (CAP).
Recently, the ENDURANCE trial evaluated the HVAD for DT in the largest multicenter, randomized, controlled trial (RCT) involving VADs to date, with 446 patients enrolled prospectively at 48 different hospitals in the United States. Preliminary results of the ENDURANCE trial showed noninferiority in the HVAD treatment group, with primary endpoint of stroke-free survival at 2 years of 55% as compared to 57.4% in the control group (p = 0.0060). Enrollment in the ENDURANCE supplemental trial involving a second cohort of 310 HVAD patients and 155 controls at 50 different nationwide centers has concluded and is expected to confirm the results of the initial cohort in premarket analysis of the HVAD for DT (42) .
Head-to-head trials comparing survival in patients bridged to transplant with VADs as compared to TAHs have been scarce. One recent study by Cheng et al examined United Network for Organ Sharing data collected from 2005 to 2014 and found no difference in 30-day, 1-, and 3-year posttransplantation survival rates between patients bridged with biVADs as compared to those bridged with TAHs, nor did they find any difference in wait-list survival between the two groups (43) . Nevertheless, limited data regarding patients' survival to discharge after initial TAH implantation remains below 50% and likely accounts for the disproportionately low number of patients receiving heart transplantation after TAH support as compared to those bridged with LVADs (1.7% vs. 44.8%) (44, 45) .
Complications
Bleeding Gastrointestinal bleeds (GIB) are the most common location of bleeds in patients with MCS devices. Singlecenter studies report a wide range of GIB rates between 10% and 61% (46) (47) (48) (49) . Aggregate data from a recent meta-analysis by Draper et al showed a pooled event rate for GIB in 1697 patients with CF-VAD devices reported in 17 different studies to be 23% (95% CI, 20-26%), with recurrence rates averaging 9.3% (95% CI, 7.1-12%). The upper gastrointestinal tract was the most common location of GIB found in 48% (95% CI, 39-57%) of study patients, and angiodysplasias accounted for the largest single etiology of GIB found in 29% of patients (48) . Despite the increased incidence of GIB with CF devices, however, mortality from GIB in the CF device era was actually lower than that in the previous pulsatile device era (20.9% vs. 43 .7%) and was also not significantly increased when compared with mortality rates in VAD patients hospitalized without GIB from either era (50) . These data appear to be in line with the HeartMate II DT trial, which showed no significant difference in bleeding events requiring blood transfusion or surgery with CF-VADs as compared to the pulsatile flow HeartMate XVE device (81% vs. 76%, p = 0.06, and 30% vs. 15%, p = 0.57, respectively) (38) . Furthermore, experience with CF VAD devices may have led to (a) decreasing incidence of bleeds as evidenced by INTER-MACS data showing bleeds occurring at 1.21 times the rate in the initial 2008-2011 CF-VAD era as compared to the more recent 2012-2014 CF-VAD era (p < 0.0001) (10), as well as (b) decreasing mortality associated with GIB as shown by pooled data from Draper et al, where all-cause mortality in CF-VAD patients without GIBs were actually found to have higher incidents of all-cause mortality when compared to CF-VAD patients with GIB (27.3% vs. 23%) (48) .
Thrombosis
Paradoxically, patients with CF MCS devices appear to also have an increased risk of hypercoagulability. Frequency of cerebrovascular events is variable, with stroke rates ranging from 2% to 42% in the CF VAD population and transient ischemic attacks in 2-5% (51-54). Of more recent concern, pump thrombosis has been reported at sharply increasing rates in postmarket analysis. Starling et al found rates of pump thrombosis in HeartMate II LVAD patients had risen by 6.2% over 2 years, from 2.2% (95% CI, 1.5 to 3.4) at 3 months postimplantation in 2011 to 8.4% (95% CI, 5.0 to 13.9) in 2013 (55). These results were corroborated by two other institutions as well as by INTERMACS, which reviewed data from 6251 HeartMate II LVAD implantations performed from 2008 through 2012 in their database and found a more modest albeit significant increase of pump thrombosis rates by 3% at 6 months postimplantation, when comparing data from April 2008 through May 2011 to that from May 2011 to March 2013 (2% vs. 5%, p < 0.0001) (56) . Follow-up data from the INTERMACS showed a peak rate of pump thrombosis at 8% in 2013 but a subsequent decline back down to 5% at 6 months postimplantation in 2014. Moreover, recent data from Klodell et al demonstrated suspected HeartMate II pump thrombosis rates of 3.6%, 5.7%, and 3.6% at 3-, 6-, and 12-months postimplantation, respectively, when pooling data from 666 patients implanted at seven different centers in the United States (57) . Limited data from Najjar et al and the ADVANCE trial investigators showed similar rates of pump thrombosis in HVAD patients, with 4% of patients experiencing pump thrombosis at 6 months postimplantation and no significant difference found between patients implanted for BTT versus CAP (58) . As previously mentioned, the magnetically levitated, centrifugal flow CF VAD HM3 has demonstrated superiority in pump thrombosis rates at 6 months postimplantation when compared to the commercially available axial flow CF VAD Heartmate II (41) . While there are currently no society guidelines regarding prevention of pump thrombosis, the PREVENT (PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management) trial recently produced prospective data from 300 patients in a multicenter, nonrandomized study examining the effect of adherence to key recommendations in reducing rates of pump thrombosis. The study included a set of 12 recommendations focusing on surgical implantation technique, anticoagulation and blood pressure parameters, and pump speed management which, when employed, resulted in a significant reduction in risk of pump thrombosis (1.9% vs. 8.9%, p < 0.01) and composite risk of thrombosis-related events (5.7% vs. 17.7%, p < 0.01) (59) .
Infection
Infections are categorized by different sites on the MCS apparatus and include most commonly driveline infections, but also pocket infections, and pump or cannula infections. Skin flora including gram-positive Staphylococcus aureus and coagulase-negative staphylococci are most often the causative agents in external driveline infections; however, internal hardware is also susceptible to colonization and infection of surrounding tissue by other host organisms such as Serratia, Klebsiella, and Enteroccocus species, Pseudomonas aeruginosa, and in up to 10% of cases, fungi such as Candida species (60) . Infection rates have been reduced steadily over the years, from 38% of all patients implanted in the first year of INTERMACS reporting to 17.6% in the era of CF VADS (2008-2014) with an even more dramatic reduction in sepsis mortality rates from 41% as reported in the REMATCH trial to 8.8% in the latest INTERMACS report from 2014 (10, 23, 30) .
Future Studies
Investigational device trials Two clinical trials involving use of the Syncardia TAH are currently in recruitment. The Syncardia 50 mL TAH-t as a BTT (NCT02459054) began recruiting patients in July 2015 and aims to demonstrate safety and efficacy in patients who have biventricular failure and who are ineligible for transplantation and VAD implantation. The study includes three arms of adult, pediatric, and secondary patients who meet less stringent enrollment criteria and is expected to complete data collection by 2018. Initial experience with the Syncardia TAH as BTT by Copeland et al showed overall 1-year survival rates of 70% compared to 31% in the control group (p < 0.001), with 79% survival to transplantation and 1 year posttransplantation survival rate of 86% in the treatment group. Expanding use of the TAH, the Syncardia 70 mL TAH-t for DT (NCT02232659) trial will study adult recipients in two arms, a primary and secondary less stringent enrollment criteria arm with the primary endpoints of survival and freedom from debilitating stroke at 6 months postimplant.
With regard to VADs, the Thoratec HM3 is currently being studied in two separate trials examining survival at 24 months postimplantation: the multicenter, international ELEVATE trial (NCT02497950), and the US-based MOMENTUM 3 CAP trial (NCT02892955) (61) .
Earlier-stage implantation Implanting durable MCS devices in patients with earlier stages of HF remains controversial due to paucity of strong evidence supporting benefit. Most recent INTER-MACS data have shown that 1-(82% vs. 82%, p = 0.06), and 3-(61% vs. 58%, p = 0.06) year survival rates are nearly identical among implanted patients from ambulatory HF classes 4-7 as compared to those in sicker classes of 2-3, demonstrating no clear benefit in mortality with earlier-stage implantation. Further risk stratification from INTERMACS has shown that once implanted, ambulatory HF patients had the same top four causes of death (neurologic event, multisystem organ failure, withdrawal of support, and major infection) as those from classes 2-3, and were even slightly more susceptible to serious adverse events such as stroke (14.1% vs. 13.2%, p = 0.003), pump-related infection (18.4% vs. 17.5%, p = 0.04), and rehospitalization (75.1% vs. 71.6%, p = 0.009) at 36 months. Perhaps most impactful are data demonstrating that ambulatory HF patients who receive durable MCS device implants have no clear advantage in access to organs for transplantation, with 39.2% of class 4-7 versus 37.9% of class 2-3 advanced HF patients receiving transplants at 1 year, though it should be noted that goals of therapy at initial enrollment based on INTERMACS class is not reported (10) .
Proponents of earlier-stage device implantation, however, point to mounting evidence that ambulatory HF patients have a markedly reduced risk of developing RHF, with only 2.3% developing RHF at 6 months postimplantation as compared to 3.9% in INTERMACS classes 2-3 versus 11.3% in INTERMACS class 1. If risk factors for mortality such as RHF, stroke, and infection can be modified in ambulatory HF patients, older age has not been shown to have a drastically lesser effect on 1-year survival in this group than it does in other INTERMACS classes (10) . In order to foster future research endeavors, Meda-MACS, the medical arm of INTERMACS, started data collection in 2012 on device-na€ ıve, INTERMACS class 5 and 6 ambulatory HF patients who may be considered for earlier-stage implantation. Preliminary results from 144 patients across 11 US transplant and VAD centers show that transplant and device-ineligible, ambulatory HF patients had higher mortality and lower rates of evaluation for advanced therapies than those who were DT-LVAD eligible or transplant eligible did, presenting an opportunity for earlier intervention and improved outcomes in this patient group (62 Results from the first 2 years of data collection showed more LVAD-treated patients met the composite primary endpoint of survival and improvement in 6-min walk test distance of ≥75 m as compared to OMM controls (30% vs. 12%, p = 0.012); however, isolated survival benefit was only seen in the as-treated group and no significant difference was seen in intent-totreat survival between the groups (70 AE 5% vs. 63 AE 5%, p = 0.307). These differences could potentially be attributed to the fact that OMM group participants were allowed a delayed LVAD at any time throughout the study, which 30% of this group eventually received. Higher rates of almost all adverse events (AEs) were seen in the LVAD group versus OMM, with the most common AE being gastrointestinal bleeding; however, despite this, patients treated with LVADs reported greater improvements in functional capacity, quality of life, and depression scores. The authors postulated that these findings were potentially due to patient's willingness to accept this "trade off," suggesting a potential move toward earlier referrals for long-term MCS device therapy (63, 64) .
Bridge to recovery
The pathophysiology of progression of cardiomyopathy is described as a chronic volume and pressure overload state contributing to myocardial remodeling. Recent studies reveal the potential utility in implantation of MCS devices to support myocardial recovery with the anticipation of ultimately weaning and explanting these devices. To this end, a number of protocols including the Harefield Protocol, which combines mechanical unloading of the ventricle with an LVAD with aggressive anti-remodeling drug therapy followed by a b2-adrenergic-receptor agonist clenbuterol, have been developed and implemented with varied recovery rates ranging from 4.5 to 73% (65) (66) (67) . Ongoing studies have also demonstrated the potential role of MCS devices paired with injecting stem cells in myocardial recovery. In a small multicenter RCT of 30 patients, injection of allogenic mesenchymal precursor cells (MPC) concurrently with LVAD implantation resulted in successful weaning of 50% of patients to minimum LVAD pump speeds for 30 min without signs of hypoperfusion on a 6-min walk test. However, physiologic data did not support regression of cardiomyopathy and statistical analysis did not show a survival benefit in the MPCtreated group (68) .
Comparison of device therapy to transplantation
New trends in HF research aim to compare outcomes of MCS destination therapy directly with heart transplantation. Based on data from the International Society for Heart and Lung Transplantation collected from 1982 to 2011, cumulative survival in heart transplant patients is 84% at 1-year posttransplantation and 69% at 5 years, with mean survival of 10.9 years. Patients who have survived the first year posttransplant, however, have an increased 5-year survival rate of 85%, and mean survival reaches 13.4 years (35, 69, 70) . This is in comparison to cumulative survival rates of 80% at 1 year and 70% at 2 years for MCS implantation under all strategies, which poses an interesting question of whether DT survival rates could ever match that of transplantation in the definitive treatment of end-stage HF.
Though no prospective trials have been undertaken to directly compare MCS device therapy versus cardiac transplantation in the long term, retrospective data from Daneshmand et al have examined outcomes of 146 patients treated with CF LVADs as destination therapy in comparison to 62 patients who underwent extended criteria cardiac transplantation (ECCT), a therapeutic option involving provision of marginal donor organs to patients who are excluded from standard criteria cardiac transplantation. Two-year mortality estimates were reported at 11.2% in the CF LVAD group and 27.3% in the ECCT group; however, this difference was not significant after statistical adjustments to account for bias in ECCT selection (p = 0.346). The study further reported no significant differences in index hospitalization lengths of stay, and significantly higher renal function in CF LVAD recipients as compared to ECCT patients, with 41% versus 18% of patients having an estimated glomerular filtration rate of greater than 60 mL/min/1.73 m 2 at 1 year posttreatment, respectively (71) .
Conclusion
Treatment of advanced HF remains a fast-growing field that has seen expansive growth and development in the past 3 decades with the introduction of cardiac transplantation and subsequently device support. Since 2013, the number of durable MCS devices implanted yearly has now surpassed that of heart transplantation (28) . Survival rates and outcomes from MCS therapy have now almost matched that of transplantation, and with further technologic advances and data from continued study, it is posited that MCS device therapy may soon serve to comparably alleviate the burden of HF in light of scarce donor organ supply.
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